Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer

Cell Death and Differentiation

Volumn 23, Issue 6, 2016, Pages 962-978

  Birge, R B ^a   Boeltz, S ^b   Kumar, S ^a   Carlson, J ^c   Wanderley, J ^d   Calianese, D ^a   Barcinski, M ^e   Brekken, R A ^f   Huang, X ^f   Hutchins, J T ^c   Freimark, B ^c   Empig, C ^c   Mercer, J ^g   Schroit, A J ^h   Schett, G ^b   Herrmann, M ^b  

^a University of Medicine and Dentistry of New Jersey   (United States)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c Department of Research and Development   (United States)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e INSTITUTO OSWALDO CRUZ   (Brazil)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOCORTIN 5; MONOCLONAL ANTIBODY; OPSONIN; PHOSPHATIDYLSERINE; PLASMA PROTEIN; PROTEIN; SCRAMBLASE; ANTIBODY; APOPTOSIS REGULATORY PROTEIN; CELL SURFACE RECEPTOR; MEMBRANE PROTEIN; PHOSPHATIDYLSERINE RECEPTOR;

APOPTOSIS; AUTOIMMUNITY; CELL DEATH; CELL STRESS; EFFEROCYTOSIS; HOMEOSTASIS; IMMUNE RESPONSE; INFECTION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; PROTIST; REVIEW; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; COMMUNICABLE DISEASE; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOIMMUNITY; COMMUNICABLE DISEASES; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASMS; PHOSPHATIDYLSERINES; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 84959222190     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2016.11     Document Type: Review

References (135)

1. Leventis PA, Grinstein S. The distribution and function of phosphatidylserine in cellular membranes. Annu Rev Biophys 2010; 39: 407-427
2. Schroit AJ, Madsen JW, Tanaka Y. In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J Biol Chem 1985; 260: 5131-5138
3. Kay JG, Koivusalo M, Ma X, Wohland T, Grinstein S. Phosphatidylserine dynamics in cellular membranes. Mol Biol Cell 2012; 23: 2198-2212
4. Stone SJ, Vance JE. Phosphatidylserine synthase-1 and -2 are localized to mitochondriaassociated membranes. J Biol Chem 2000; 275: 34534-34540
5. Arikketh D, Nelson R, Vance JE. Defining the importance of phosphatidylserine synthase-1 (PSS1): unexpected viability of PSS1-deficient mice. J Biol Chem 2008; 283: 12888-12897
6. Kay JG, Grinstein S. Phosphatidylserine-mediated cellular signaling. Adv Exp Med Biol 2013; 991: 177-193
7. Nikawa JI, Yamashita S. Characterization of phosphatidylserine synthase from Saccharomyces cerevisiae and a mutant defective in the enzyme. Biochim Biophys Acta 1981; 665: 420-426
8. Sousa SB, Jenkins D, Chanudet E, Tasseva G, Ishida M, Anderson G., et al. Gain-of-function mutations in the phosphatidylserine synthase 1 (PTDSS1) gene cause Lenz-Majewski syndrome. Nat Genet 2014; 46: 70-76
9. Lemmon M.A. Membrane recognition by phospholipid-binding domains. Nat Rev Mol Cell Biol 2008; 9: 99-111
10. Bevers EM, Comfurius P, Van Rijn JL, Hemker HC, Zwaal RF. Generation of prothrombinconverting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem 1982; 122: 429-436
11. Appelt U, Sheriff A, Gaipl US, Kalden JR, Voll RE, Herrmann M. Viable, apoptotic and necrotic monocytes expose phosphatidylserine: cooperative binding of the ligand Annexin V to dying but not viable cells and implications for PS-dependent clearance. Cell Death Differ 2005; 12: 194-196
12. Callahan MK, Williamson P, Schlegel RA. Surface expression of phosphatidylserine on macrophages is required for phagocytosis of apoptotic thymocytes. Cell Death Differ 2000; 7: 645-653
13. Hochreiter-Hufford AE, Lee CS, Kinchen JM, Sokolowski JD, Arandjelovic S, Call JA., et al. Phosphatidylserine receptor BAI1 and apoptotic cells as new promoters of myoblast fusion. Nature 2013; 497: 263-267
14. Yoshida H, Kawane K, Koike M, Mori Y, Uchiyama Y, Nagata S. Phosphatidylserinedependent engulfment by macrophages of nuclei from erythroid precursor cells. Nature 2005; 437: 754-758
15. Dillon SR, Mancini M, Rosen A, Schlissel MS. Annexin V binds to viable B cells and colocalizes with a marker of lipid rafts upon B cell receptor activation. J Immunol 2000; 164: 1322-1332
16. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 1991; 51: 3062-3066
17. Kim R, Emi M, Tanabe K. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol Ther 2005; 4: 924-933
18. Taylor DD, Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-Associated immunosuppressive microenvironments. Semin Immunopathol 2011; 33: 441-454
19. Suzuki J, Umeda M, Sims PJ, Nagata S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 2010; 468: 834-838
20. Suzuki J, Denning DP, Imanishi E, Horvitz HR, Nagata S. Xk-related protein 8 and CED-8 promote phosphatidylserine exposure in apoptotic cells. Science 2013; 341: 403-406
21. Yang H, Kim A, David T, Palmer D, Jin T, Tien J., et al. TMEM16F forms a Ca2+-Activated cation channel required for lipid scrambling in platelets during blood coagulation. Cell 2012; 151: 111-122
22. Suzuki J, Fujii T, Imao T, Ishihara K, Kuba H, Nagata S. Calcium-dependent phospholipid scramblase activity of TMEM16 protein family members. J Biol Chem 2013; 288: 13305-13316
23. Stanfield GM, Horvitz HR. The ced-8 gene controls the timing of programmed cell deaths in C. elegans. Mol Cell 2000; 5: 423-433
24. Suzuki J, Imanishi E, Nagata S. Exposure of phosphatidylserine by Xk-related protein family members during apoptosis. J Biol Chem 2014; 289: 30257-30267
25. Segawa K, Suzuki J, Nagata S. Constitutive exposure of phosphatidylserine on viable cells. Proc Natl Acad Sci USA 2011; 108: 19246-19251
26. Segawa K, Kurata S, Yanagihashi Y, Brummelkamp TR, Matsuda F, Nagata S. Caspasemediated cleavage of phospholipid flippase for apoptotic phosphatidylserine exposure. Science 2014; 344: 1164-1168
27. Menke M, Ross M, Gerke V, Steinem C. The molecular arrangement of membrane-bound annexin A2-S100A10 tetramer as revealed by scanning force microscopy. Chembiochem 2004; 5: 1003-1006
28. Stegh AH, Herrmann H, Lampel S, Weisenberger D, Andra K, Seper M., et al. Identification of the cytolinker plectin as a major early in vivo substrate for caspase 8 during CD95- And tumor necrosis factor receptor-mediated apoptosis. Mol Cell Biol 2000; 20: 5665-5679
29. Ishii H, Mori T, Shiratsuchi A, Nakai Y, Shimada Y, Ohno-Iwashita Y., et al. Distinct localization of lipid rafts and externalized phosphatidylserine at the surface of apoptotic cells. Biochem Biophys Res Commun 2005; 327: 94-99
30. Meyer AS, Zweemer AJ, Lauffenburger DA. The AXL receptor is a sensor of ligand spatial heterogeneity. Cell Syst 2015; 1: 25-36
31. Hamon Y, Broccardo C, Chambenoit O, Luciani MF, Toti F, Chaslin S., et al. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat Cell Biol 2000; 2: 399-406
32. Lee SH, Meng XW, Flatten KS, Loegering DA, Kaufmann SH. Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm. Cell Death Differ 2013; 20: 64-76
33. Kay JG, Grinstein S. Sensing phosphatidylserine in cellular membranes. Sensors (Basel) 2011 11 1744-1755
34. Tyurin VA, Balasubramanian K, Winnica D, Tyurina YY, Vikulina AS, He RR., et al. Oxidatively modified phosphatidylserines on the surface of apoptotic cells are essential phagocytic 'eat-me' signals: cleavage and inhibition of phagocytosis by Lp-PLA2. Cell Death Differ 2014; 21: 825-835
35. Jiang J, Kini V, Belikova N, Serinkan BF, Borisenko GG, Tyurina YY., et al. Cytochrome c release is required for phosphatidylserine peroxidation during Fas-triggered apoptosis in lung epithelial A549 cells. Lipids 2004; 39: 1133-1142
36. Kagan VE, Tyurin VA, Jiang J, Tyurina YY, Ritov VB, Amoscato AA., et al. Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat Chem Biol 2005; 1: 223-232
37. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997; 390: 350-351
38. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL., et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46: 191-201
39. Ren Y, Tang J, Mok MY, Chan AW, Wu A, Lau CS. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2888-2897
40. Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010; 6: 280-289
41. Ravichandran KS. Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity 2011; 35: 445-455
42. Bournazou I, Pound JD, Duffin R, Bournazos S, Melville LA, Brown SB., et al. Apoptotic human cells inhibit migration of granulocytes via release of lactoferrin. J Clin invest 2009; 119: 20-32
43. Meesmann HM, Fehr EM, Kierschke S, Herrmann M, Bilyy R, Heyder P., et al. Decrease of sialic acid residues as an eat-me signal on the surface of apoptotic lymphocytes. J Cell Sci 2010; 123: 3347-3356
44. Biermann M, Maueroder C, Brauner JM, Chaurio R, Janko C, Herrmann M., et al. Surface code-biophysical signals for apoptotic cell clearance. Phys Biol 2013; 10: 065007
45. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 2002; 109: 41-50
46. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: 1241-1250
47. Munoz LE, Janko C, Grossmayer GE, Frey B, Voll RE, Kern P., et al. Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1733-1742
48. Kimani SG, Geng K, Kasikara C, Kumar S, Sriram G, Wu Y., et al. Contribution of defective ps recognition and efferocytosis to chronic inflammation and autoimmunity. Front Immunol 2014; 5: 566
49. Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, Roubey RA., et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 2002; 196: 135-140
50. Tibrewal N, Wu Y, D'Mello V, Akakura R, George TC, Varnum B., et al. Autophosphorylation docking site Tyr-867 in Mer receptor tyrosine kinase allows for dissociation of multiple signaling pathways for phagocytosis of apoptotic cells and down-modulation of lipopolysaccharideinducible NF-kappaB transcriptional activation. J Biol Chem 2008; 283: 3618-3627
51. Cvetanovic M, Ucker DS. Innate immune discrimination of apoptotic cells: repression of proinflammatory macrophage transcription is coupled directly to specific recognition. J Immunol 2004; 172: 880-889
52. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007; 131: 1124-1136
53. Carrera Silva EA, Chan PY, Joannas L, Errasti AE, Gagliani N, Bosurgi L., et al. T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response. Immunity 2013; 39: 160-170
54. Albacker LA, Karisola P, Chang YJ, Umetsu SE, Zhou M, Akbari O., et al. TIM-4, a receptor for phosphatidylserine, controls adaptive immunity by regulating the removal of antigenspecific T cells. J Immunol 2010; 185: 6839-6849
55. DeKruyff RH, Bu X, Ballesteros A, Santiago C, Chim YL, Lee HH., et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol 2010; 184: 1918-1930
56. Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. Identification of Tim4 as a phosphatidylserine receptor. Nature 2007; 450: 435-439
57. Santiago C, Ballesteros A, Martinez-Munoz L, Mellado M, Kaplan GG, Freeman GJ., et al. Structures of T cell immunoglobulin mucin protein 4 show a metal-Ion-dependent ligand binding site where phosphatidylserine binds. Immunity 2007; 27: 941-951
58. Santiago C, Ballesteros A, Tami C, Martinez-Munoz L, Kaplan GG, Casasnovas JM. Structures of T Cell immunoglobulin mucin receptors 1 and 2 reveal mechanisms for regulation of immune responses by the TIM receptor family. Immunity 2007; 26: 299-310
59. Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 2010; 235: 172-189
60. Ferris RL, Lu B, Kane LP. Too much of a good thing?. Tim-3 and TCR signaling in T cell exhaustion. J Immunol 2014; 193: 1525-1530
61. Rangachari M, Zhu C, Sakuishi K, Xiao S, Karman J, Chen A., et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat Med 2012; 18: 1394-1400
62. Lee J, Su EW, Zhu C, Hainline S, Phuah J, Moroco JA., et al. Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. Mol Cell Biol 2011; 31: 3963-3974
63. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H., et al. Tumorinfiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012; 13: 832-842
64. Amara A, Mercer J. Viral apoptotic mimicry. Nat Rev Microbiol 2015; 13: 461-469
65. Morizono K, Chen IS. Role of phosphatidylserine receptors in enveloped virus infection. J Virol 2014; 88: 4275-4290
66. Chen YH, Du W, Hagemeijer MC, Takvorian PM, Pau C, Cali A., et al. Phosphatidylserine vesicles enable efficient en bloc transmission of enteroviruses. Cell 2015; 160: 619-630
67. Feng Z, Hensley L, McKnight KL, Hu F, Madden V, Ping L., et al. A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature 2013; 496: 367-371
68. Maruri-Avidal L, Weisberg AS, Moss B. Direct formation of vaccinia virus membranes from the endoplasmic reticulum in the absence of the newly characterized L2-interacting protein A30.5. J Virol 2013; 87: 12313-12326
69. Lorizate M, Sachsenheimer T, Glass B, Habermann A, Gerl MJ, Krausslich HG., et al. Comparative lipidomics analysis of HIV-1 particles and their producer cell membrane in different cell lines. Cell Microbiol 2013; 15: 292-304
70. Fairn GD, Schieber NL, Ariotti N, Murphy S, Kuerschner L, Webb RI., et al. High-resolution mapping reveals topologically distinct cellular pools of phosphatidylserine. J Cell Biol 2011; 194: 257-275
71. Mercer J, Helenius A. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 2008; 320: 531-535
72. Mercer J, Helenius A. Apoptotic mimicry: phosphatidylserine-mediated macropinocytosis of vaccinia virus. Ann NY Acad Sci 2010; 1209: 49-55
73. Bhattacharyya S, Zagorska A, Lew ED, Shrestha B, Rothlin CV, Naughton J., et al. Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe 2013; 14: 136-147
74. Liu L, Xu Z, Fuhlbrigge RC, Pena-Cruz V, Lieberman J, Kupper TS. Vaccinia virus induces strong immunoregulatory cytokine production in healthy human epidermal keratinocytes: a novel strategy for immune evasion. J Virol 2005; 79: 7363-7370
75. Dowall SD, Graham VA, Corbin-Lickfett K, Empig C, Schlunegger K, Bruce CB., et al. Effective binding of a phosphatidylserine-targeting antibody to Ebola virus infected cells and purified virions. J Immunol Res 2015; 2015: 347903
76. Soares MM, King SW, Thorpe PE. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 2008; 14: 1357-1362
77. Moody MA, Liao HX, Alam SM, Scearce RM, Plonk MK, Kozink DM., et al. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med 2010; 207: 763-776
78. Shibata T, Habiel DM, Coelho AL, Kunkel SL, Lukacs NW, Hogaboam CM. Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthma. J Immunol 2014; 192: 3569-3581
79. Czuczman MA, Fattouh R, Van Rijn JM, Canadien V, Osborne S, Muise AM., et al. Listeria monocytogenes exploits efferocytosis to promote cell-to-cell spread. Nature 2014; 509: 230-234
80. Martin CJ, Booty MG, Rosebrock TR, Nunes-Alves C, Desjardins DM, Keren I., et al. Efferocytosis is an innate antibacterial mechanism. Cell Host Microbe 2012; 12: 289-300
81. Ameisen JC, Idziorek T, Billaut-Mulot O, Loyens M, Tissier JP, Potentier A., et al. Apoptosis in a unicellular eukaryote (Trypanosoma cruzi): implications for the evolutionary origin and role of programmed cell death in the control of cell proliferation, differentiation and survival. Cell Death Differ 1995; 2: 285-300
82. Welburn SC, Dale C, Ellis D, Beecroft R, Pearson TW. Apoptosis in procyclic Trypanosoma brucei rhodesiense in vitro. Cell Death Differ 1996; 3: 229-236
83. Van Zandbergen G, Luder CG, Heussler V, Duszenko M. Programmed cell death in unicellular parasites: a prerequisite for sustained infection?. Trends Parasitol 2010; 26: 477-483
84. Deponte M. Programmed cell death in protists. Biochim Biophys Acta 2008; 1783: 1396-1405
85. Marinho FA, Goncalves KC, Oliveira SS, Goncalves DS, Matteoli FP, Seabra SH., et al. The calpain inhibitor MDL28170 induces the expression of apoptotic markers in Leishmania amazonensis promastigotes. PLoS One 2014; 9: e87659
86. Wanderley JL, Pinto da Silva LH, Deolindo P, Soong L, Borges VM, Prates DB., et al. Cooperation between apoptotic and viable metacyclics enhances the pathogenesis of Leishmaniasis. PLoS One 2009; 4: e5733
87. El-Hani CN, Borges VM, Wanderley JL, Barcinski M.A. Apoptosis and apoptotic mimicry in Leishmania: an evolutionary perspective. Front Cell Infect Microbiol 2012; 2: 96
88. Kaczanowski S, Sajid M, Reece SE. Evolution of apoptosis-like programmed cell death in unicellular protozoan parasites. Parasit Vectors 2011; 4: 44
89. Nguewa PA, Fuertes MA, Valladares B, Alonso C, Perez JM. Programmed cell death in trypanosomatids: a way to maximize their biological fitness?. Trends Parasitol 2004; 20: 375-380
90. Wanderley JL, Moreira ME, Benjamin A, Bonomo AC, Barcinski M.A. Mimicry of apoptotic cells by exposing phosphatidylserine participates in the establishment of amastigotes of Leishmania (L) amazonensis in mammalian hosts. J Immunol 2006; 176: 1834-1839
91. De Freitas Balanco JM, Moreira ME, Bonomo A, Bozza PT, Amarante-Mendes G, Pirmez C., et al. Apoptotic mimicry by an obligate intracellular parasite downregulates macrophage microbicidal activity. Curr Biol 2001; 11: 1870-1873
92. Santos TA, Portes Jde A, Damasceno-Sa JC, Caldas LA, Souza W, Damatta RA., et al. Phosphatidylserine exposure by Toxoplasma gondii is fundamental to balance the immune response granting survival of the parasite and of the host. PLoS One 2011; 6: e27867
93. Damatta RA, Seabra SH, Deolindo P, Arnholdt AC, Manhaes L, Goldenberg S., et al. Trypanosoma cruzi exposes phosphatidylserine as an evasion mechanism. FEMS Microbiol Lett 2007; 266: 29-33
94. Campos-Salinas J, Leon-Guerrero D, Gonzalez-Rey E, Delgado M, Castanys S, Perez- Victoria JM., et al. LABCG2, a new ABC transporter implicated in phosphatidylserine exposure, is involved in the infectivity and pathogenicity of Leishmania. PLoS Negl Trop Dis 2013; 7: e2179
95. Van Zandbergen G, Bollinger A, Wenzel A, Kamhawi S, Voll R, Klinger M., et al. Leishmania disease development depends on the presence of apoptotic promastigotes in the virulent inoculum. Proc Natl Acad Sci USA 2006; 103: 13837-13842
96. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 2002; 62: 6132-6140
97. Bondanza A, Zimmermann VS, Rovere-Querini P, Turnay J, Dumitriu IE, Stach CM., et al. Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J Exp Med 2004; 200: 1157-1165
98. Kelleher RJ, Balu-Iyer S, Loyall JL, Sacca AJ, Shenoy GN, Peng P., et al. Extracellular vesicles present in human ovarian tumor microenvironments induce a phosphatidylserine dependent arrest in the T cell signaling cascade. Cancer Immunol Res 2015; 3: 1269-1278
99. Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 2014; 14: 769-785
100. Cook RS, Jacobsen KM, Wofford AM, DeRyckere D, Stanford J, Prieto AL., et al. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. J Clin Invest 2013; 123: 3231-3242
101. Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB., et al. Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. J Clin Invest 2014; 124: 4737-4752
102. Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S., et al. The E3 ligase Cblb and TAM receptors regulate cancer metastasis via natural killer cells. Nature 2014; 507: 508-512
103. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015; 14: 561-584
104. Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005; 6: 449-461
105. Lima LG, Chammas R, Monteiro RQ, Moreira ME, Barcinski M.A. Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserinedependent manner. Cancer Lett 2009; 283: 168-175
106. Munoz LE, Franz S, Pausch F, Furnrohr B, Sheriff A, Vogt B., et al. The influence on the immunomodulatory effects of dying and dead cells of Annexin V. J Leukoc Biol 2007; 81: 6-14
107. Stach CM, Turnay X, Voll RE, Kern PM, Kolowos W, Beyer TD., et al. Treatment with annexin V increases immunogenicity of apoptotic human T-cells in Balb/c mice. Cell Death Differ 2000; 7: 911-915
108. Frey B, Schildkopf P, Rodel F, Weiss EM, Munoz LE, Herrmann M., et al. AnnexinA5 renders dead tumor cells immunogenic-implications for multimodal cancer therapies. J Immunotoxicol 2009; 6: 209-216
109. Chaurio RA, Janko C, Munoz LE, Frey B, Herrmann M, Gaipl US. Phospholipids: key players in apoptosis and immune regulation. Molecules (Basel, Switzerland) 2009; 14: 4892-4914
110. De Meyer S, Gong Z, Depla E, Maertens G, Yap SH. Involvement of phosphatidylserine and non-phospholipid components of the hepatitis B virus envelope in human Annexin V binding and in HBV infection in vitro. J Hepatol 1999; 31: 783-790
111. DeRose P, Thorpe PE, Gerber DE. Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. Immunotherapy 2011; 3: 933-944
112. Huang X, Bennett M, Thorpe PE. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res 2005; 65: 4408-4416
113. Beck AW, Luster TA, Miller AF, Holloway SE, Conner CR, Barnett CC., et al. Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer 2006; 118: 2639-2643
114. He J, Yin Y, Luster TA, Watkins L, Thorpe PE. Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. Clin Cancer Res 2009; 15: 6871-6880
115. Yin Y, Huang X, Lynn KD, Thorpe PE. Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation. Cancer immunol Res 2013; 1: 256-268
116. Chalasani P, Marron M, Roe D, Clarke K, Iannone M, Livingston RB., et al. A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer. Cancer Med 2015; 4: 1051-1059
117. Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS., et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer 2014; 86: 231-236
118. Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS., et al. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011; 17: 6888-6896
119. Callahan MK, Popernack PM, Tsutsui S, Truong L, Schlegel RA, Henderson AJ. Phosphatidylserine on HIV envelope is a cofactor for infection of monocytic cells. J Immunol 2003; 170: 4840-4845
120. Divangahi M, Chen M, Gan H, Desjardins D, Hickman TT, Lee DM., et al. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat Immunol 2009; 10: 899-906
121. Chen M, Divangahi M, Gan H, Shin DS, Hong S, Lee DM., et al. Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med 2008; 205: 2791-2801
122. Eda S, Sherman IW. Cytoadherence of malaria-infected red blood cells involves exposure of phosphatidylserine. Cell Physiol Biochem 2002; 12: 373-384
123. Anderton P, Wild TF, Zwingelstein G. Phospholipids in a measles virus persistent infection: modification of fatty acid metabolism and fatty acid composition of released virus. J Gen Virol 1982; 62: 249-258
124. Kawai Y. Characteristic cellular fatty acid composition and an ornithine-containing lipid as a new type of hemagglutinin in Bordetella pertussis. Dev Biol Stand 1985; 61: 249-254
125. Rauch G, Gambale F, Montal M. Tetanus toxin channel in phosphatidylserine planar bilayers: conductance states and pH dependence. Eur Biophys J 1990; 18: 79-83
126. Belisle JT, Brandt ME, Radolf JD, Norgard MV. Fatty acids of Treponema pallidum and Borrelia burgdorferi lipoproteins. J Bacteriol 1994; 176: 2151-2157
127. Mercer J, Mazzon M. Lipid interactions during virus entry and infection. Cell Microbiol 2014; 16: 1493-1502
128. Van Zandbergen G, Klinger M, Mueller A, Dannenberg S, Gebert A, Solbach W., et al. Cutting edge: neutrophil granulocyte serves as a vector for Leishmania entry into macrophages. J Immunol 2004; 173: 6521-6525
129. De Souza W, Morgado-Diaz JA, Cunha-e-Silva NL. Cell fractionation of parasitic protozoa. Methods Mol Biol 2008; 425: 313-331
130. Digumarti R, Bapsy PP, Shan JS. A Phase Ib safety and pharmacokinetic study of bavituximab plus chemotherapy in patients with refractory advanced solid tumor malignancies. J Clin Oncol 2008; 26(Suppl): Abstract 3038
131. Tabagari D, Nemsadze G, Janjalia M, Jincharadze M, Shan J. Phase II study of bavituximab plus docetaxel in locally advanced or metastatic breast cancer. J Clin Oncol 2010; 28 (Suppl): Abstract 1042
132. Pandya SS, Wong L, Bullock AJ, Grabelsky SA, Shum MK, Shan J., et al. Randomized, open-label, phase II trial of gemcitabine with or without bavituximab in patients with nonresectable stage IV pancreatic adenocarcinoma. J Clin Oncol 2013; 31(Suppl): Abstract 4054
133. Shtivelband M, Spigel DR, Gerber DE, Jain MM, Ponomarova OV, Giorgadze D., et al. Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer. J Clin Oncol 2013; 31(Suppl): Abstract 8095
134. Grilley-Olson JE, Villaruz LC, Stinchcombe TE, Weiss J, Shan J, Vashishtha A., et al. A phase Ib study of bavituximab plus carboplatin and pemetrexed in chemotherapy naïve stage IV non-squamous non-small cell lung cancer. Presented at: Chicago Multidisciplinary Symposium on Thoracic Oncology, Chicago, IL, 2014; Abstract 215
135. Yopp AC, Singal AG, Arriaga YE, Verma UN, Shan J, Kallinteris N., et al. A phase II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2015; 33(Suppl): Abstract 4109